These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15088933)

  • 21. [Treatment of diabetes mellitus. New developments and hopes].
    Verspohl EJ
    Med Monatsschr Pharm; 2005 Jun; 28(6):193-202; quiz 203. PubMed ID: 15960421
    [No Abstract]   [Full Text] [Related]  

  • 22. Theratechnologies expands peptide portfolio in endocrinology.
    Walczak IM
    Diabetes Technol Ther; 2002; 4(5):734. PubMed ID: 12458565
    [No Abstract]   [Full Text] [Related]  

  • 23. The European Association for the Study of Diabetes Annual Meeting, 1998. Treatment of type 2 diabetes and the pathogenesis of complications.
    Bloomgarden ZT
    Diabetes Care; 1999 Jul; 22(7):1209-15. PubMed ID: 10388992
    [No Abstract]   [Full Text] [Related]  

  • 24. On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors.
    Hinke SA; McIntosh CH; Hoffmann T; Kühn-Wache K; Wagner L; Bär J; Manhart S; Wermann M; Pederson RA; Demuth HU
    Diabetes Care; 2002 Aug; 25(8):1490-1; author reply 1491-2. PubMed ID: 12145269
    [No Abstract]   [Full Text] [Related]  

  • 25. [GIP and GLP-1: multiplicity of regulator mechanisms for insulin secretion].
    Thorens B
    Journ Annu Diabetol Hotel Dieu; 2004; ():111-25. PubMed ID: 15259310
    [No Abstract]   [Full Text] [Related]  

  • 26. Discussing the role of glucagonlike peptide-I.
    Holst JJ; Orskov C
    Diabetes Care; 1992 Oct; 15(10):1440-1. PubMed ID: 1425120
    [No Abstract]   [Full Text] [Related]  

  • 27. Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDM.
    Thorens B; Waeber G
    Diabetes; 1993 Sep; 42(9):1219-25. PubMed ID: 8349031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
    Garber AJ
    Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S279-84. PubMed ID: 21525469
    [No Abstract]   [Full Text] [Related]  

  • 29. [New strategy in type 2 diabetes tested in clinical trials. Glucagon-like peptide 1 (GLP-1) affects basic caused of the disease].
    Ahrén B
    Lakartidningen; 2005 Feb 21-27; 102(8):545-9. PubMed ID: 15786905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
    Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
    J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
    Nauck MA; Meier JJ
    Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel strategies for the pharmacological management of type 2 diabetes.
    Nourparvar A; Bulotta A; Di Mario U; Perfetti R
    Trends Pharmacol Sci; 2004 Feb; 25(2):86-91. PubMed ID: 15102494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Novel therapy in type 2 diabetes: to regulate glucose metabolism naturally].
    MMW Fortschr Med; 2005 Aug; 147(31-32):54-5. PubMed ID: 16128202
    [No Abstract]   [Full Text] [Related]  

  • 36. Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes.
    Drucker DJ
    Curr Pharm Des; 2001 Sep; 7(14):1399-412. PubMed ID: 11472275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin avoidance and treatment outcomes among patients with a professional driving licence starting glucagon-like peptide 1 (GLP-1) agonists in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits.
    Thong KY; Ryder RE; Cull ML; Walton C;
    Diabet Med; 2012 May; 29(5):690-2. PubMed ID: 21988449
    [No Abstract]   [Full Text] [Related]  

  • 38. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging treatments for patients with type 2 diabetes.
    Haines ST
    Diabetes Educ; 2007; 33 Suppl 5():105S-10S. PubMed ID: 17548897
    [No Abstract]   [Full Text] [Related]  

  • 40. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
    Gefel D; Barg Y; Zimlichman R
    Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.